Business

Raumedic reshapes management team

Stefan Seuferling (left), the new Chairman of the Executive Board of Raumedic AG, and Martin Bayer, CEO and President of the U.S. business operation, plan to focus more closely on the needs of their target markets.

By Lightning Reports, Published: April 9, 2019

MILLS RIVER — The medical technology manufacturer Raumedic has re-assigned responsibilities among its top management team, naming Executive Board member Stefan Seuferling chairman of the Executive Board and shifting former chair Martin Bayer to focus on his function as CEO and President of the U.S. company and develop business in North America, the world’s largest medical technology market.

The changes by the company’s Board of Directors that took effect March 15.

“Medical technology and the pharmaceutical industry face different requirements in each economic region,” Jürgen Werner, the Chairman of the Board of Directors, said in a news release. “In addition, customers are approaching Raumedic with highly individual product requests. With the new management structure, we want to enable both companies to retain their flexibility and to be highly responsive to their respective markets.”

As the highest oversight authority for both companies, the Board of Directors works closely with the management team to ensure that the principle of “One Raumedic” is systematically applied, Werner said in describing the new structure.

Seuferling joined Raumedic AG last September as the Executive Board member responsible for strategy, from which position he leads sales activities in Europe and Asia. He also oversees the departments of Marketing Communication, Quality Management, Regulatory Affairs, as well as Projects & Services. Together with his Executive Board colleagues, Seuferling will lead the business activities of Raumedic AG as Chairman of the Executive Board.

Closer to the world’s largest medical technology market

As part of the efforts of Raumedic to enter the world’s largest medical technology and pharmaceutical market, Martin Bayer moved his office to Mills River in spring of 2018. Bayer, who has extensive experience in the medical technology market, intends to generate the same success in the USA that he produced for the global organization: Under his leadership, both sales and staffing nearly doubled from 2008 to 2018.

“The new leadership team is the next logical step in our efforts to make Raumedic increasingly agile and market-centric,” Werner said. “We have the utmost confidence in Stefan Seuferling and Martin Bayer. We are certain that they can help the entire company continue generating sustainable and profitable growth. With this goal in mind, they will remain in close dialogue in the future.”

Raumedic specializes in processing medical-grade thermoplastic polymers and silicones at five production sites in Germany and the United States.